Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ: ARQT · IEX Real-Time Price · USD
9.91
+0.32 (3.34%)
At close: Mar 28, 2024, 4:00 PM
9.88
-0.03 (-0.30%)
After-hours: Mar 28, 2024, 7:44 PM EDT

Company Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.

Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis.

The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.

Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics logo
Country United States
Founded 2016
IPO Date Jan 31, 2020
Industry Biotechnology
Sector Healthcare
Employees 296
CEO Todd Franklin Watanabe M.A.

Contact Details

Address:
3027 Townsgate Road, Suite 300
Westlake Village, California 91361
United States
Phone 805-418-5006
Website arcutis.com

Stock Details

Ticker Symbol ARQT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001787306
CUSIP Number 03969K108
ISIN Number US03969K1088
Employer ID 81-2974255
SIC Code 2834

Key Executives

Name Position
Todd Franklin Watanabe M.A. President, Chief Executive Officer and Director
Dr. Bhaskar Chaudhuri Ph.D. Co-Founder and Independent Director
Masaru Matsuda Esq., J.D. Senior Vice President, General Counsel and Corporate Secretary
Dr. Patrick E. Burnett M.D., Ph.D. Senior Vice President and Chief Medical Officer
John W. Smither CPA Chief Financial Officer
Rajvir Madan Chief Digital and Technology Officer
Latha Vairavan Vice President of Finance and Investor Relations
Courtney Barton Vice President and Chief Compliance Officer and Privacy Officer
Amanda Sheldon Head of Corporate Communications
Ayisha Jeter Head of Marketing and Market Access

Latest SEC Filings

Date Type Title
Mar 6, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 4, 2024 144 Filing
Mar 4, 2024 144 Filing
Mar 4, 2024 144 Filing
Mar 4, 2024 144 Filing
Mar 4, 2024 144 Filing
Mar 4, 2024 8-K Current Report
Mar 1, 2024 424B5 Filing
Feb 28, 2024 144 Filing